Skip to main content

Upper GI cancer surgery · UK

Oesophagogastrectomy - combined resection for tumours at the gastro-oesophageal junction.

A major upper GI cancer operation that removes the distal oesophagus and part or all of the stomach - for Siewert I–III tumours spanning the junction. Delivered by a specialist AUGIS upper GI cancer team at a high-volume UK centre.

See the pathway at a glance
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why patients choose this pathway

  • 01

    A high-volume upper GI cancer centre

    Oesophagogastrectomy belongs in an AUGIS-recognised tertiary centre with an upper GI cancer MDT - not a general list. Volume drives outcome.

  • 02

    The full MDT before a single incision

    Upper GI surgeon, medical and clinical oncology, radiology, pathology, specialist nurse and dietician - the plan is agreed by the whole team before you consent.

  • 03

    Prehab, neoadjuvant, and honest odds

    FLOT or CROSS neoadjuvant where indicated, a structured prehab window, and a plain-English conversation about survival, leak risk and life after.

The UK pathway

What an oesophagogastrectomy looks like on the AUGIS pathway.

A major cancer operation delivered on the NHS at a specialist upper GI centre. Private second opinions are available; the operation itself is not routinely private.

In short

5–8 hours in theatre · ITU 24–72 hours · hospital 10–21 days.

Approach Access route
Ivor-Lewis oesophagogastrectomy (NHS pathway) NHS-funded
McKeown 3-stage oesophagogastrectomy (NHS pathway) NHS-funded
Transhiatal oesophagogastrectomy (NHS pathway) NHS-funded
Minimally invasive / RAMIE (NHS pathway) NHS-funded
Extended total gastrectomy + lower oesophagectomy NHS-funded
Second-opinion MDT review (private) £400–£900

The right operation depends on the Siewert type of your tumour, your anatomy and your fitness. The MDT chooses the approach - you are not asked to pick between them cold.

The problem

Junction tumours don’t fit neatly into oesophagectomy or gastrectomy - they need both.

Cancers spanning the gastro-oesophageal junction demand a combined resection, a full MDT and a high-volume centre. Volume-outcome data is clear - this is not the operation to have in a low-volume unit.

  • Right operation for the right Siewert type

    Siewert I usually needs an oesophagectomy alone. Siewert II is the classic oesophagogastrectomy. Siewert III leans towards extended total gastrectomy - getting the choice right matters.

  • Full staging before anyone opens you

    CT, PET-CT, endoscopic ultrasound and staging laparoscopy with peritoneal cytology should all be done before consent - not after.

  • A high-volume centre, an experienced MDT

    30-day mortality and long-term survival are both better at high-volume UK centres. This is the single most important choice you make.

The journey

From diagnosis to recovery - the AUGIS pathway, in order.

A structured cancer pathway with clear staging, MDT decision-making, neoadjuvant therapy where appropriate, and a defined post-op recovery arc.

  1. 01

    Before

    Diagnosis and Siewert classification

    Endoscopy with biopsy pinpoints the tumour and its position relative to the gastro-oesophageal junction - Siewert I, II or III drives which operation fits.

  2. 02

    Before

    Full staging workup

    CT chest/abdo/pelvis, PET-CT to exclude metastases, endoscopic ultrasound for T and N stage, and staging laparoscopy with peritoneal cytology.

  3. 03

    Before

    Upper GI cancer MDT decision

    The whole team reviews imaging, histology and fitness together, then agrees the operation, the neoadjuvant plan and the reconstruction.

  4. 04

    Before

    Neoadjuvant chemotherapy or chemoradiotherapy

    FLOT peri-operative chemo or CROSS chemoradiotherapy is standard for locally advanced disease - surgery follows a rest interval.

  5. 05

    Before

    Prehab - exercise, nutrition, cessation

    Structured aerobic work, protein-loaded nutrition, incentive spirometry, and firm smoking and alcohol cessation in the weeks before theatre.

  6. 06

    Theatre day

    The operation - 5 to 8 hours

    Ivor-Lewis, McKeown, transhiatal, MIO/RAMIE or extended total gastrectomy with lower oesophagectomy - technique matched to Siewert type and anatomy.

  7. 07

    After

    ITU, ward, and structured recovery

    ITU 24–72 hours, hospital 10–21 days, NG tube 5–7 days, jejunostomy feeding 3–6 weeks, dietician-led rehab and lifelong nutrient monitoring.

Typical end-to-end: 3–4 months from MDT to theatre with neoadjuvant. Full functional recovery: 3–6 months after surgery.

When it fits

When an oesophagogastrectomy is the right operation.

The indications we see most often - plus the red-flag symptoms that mean an urgent GP visit and a two-week-wait upper GI referral.

  • GOJ adenocarcinoma (Siewert I–III)

    Adenocarcinoma centred on the gastro-oesophageal junction - the classic indication for a combined resection.

  • Extensive proximal gastric cancer

    Gastric cancer high on the stomach that reaches up onto the distal oesophagus and cannot be cleared by gastrectomy alone.

  • Tumours crossing the GOJ

    Cancers straddling the junction where a clear margin needs both distal oesophagus and proximal stomach removed.

  • Barrett’s HGD with junction involvement

    Occasional cases of high-grade dysplasia or early cancer in Barrett’s that reach the junction and cannot be endoscopically resected.

  • Lower oesophageal cancer into stomach

    Distal oesophageal tumours extending downwards into the cardia - resection has to take the top of the stomach with it.

  • Siewert II - centred at the GOJ

    1cm above to 2cm below the junction - usually transhiatal or transthoracic oesophagogastrectomy with gastric conduit.

  • Siewert III - subcardial gastric

    2–5cm below the junction with oesophageal involvement - extended total gastrectomy plus distal oesophagectomy, Roux-en-Y reconstruction.

  • Red flag: dysphagia, weight loss, bleeding

    Progressive difficulty swallowing, unexplained weight loss, vomiting or GI bleeding - see a GP urgently for two-week-wait upper GI referral.

Approaches and reconstruction

More than one way in - and more than one way to rebuild.

The Siewert type of your tumour, the fitness of your lungs and heart, and the anatomy of your stomach all drive which approach and which reconstruction fits.

  • Ivor-Lewis (2-stage)

    Laparotomy plus right thoracotomy with the anastomosis in the chest - the workhorse for Siewert I/II with a gastric conduit.

  • McKeown (3-stage)

    Laparotomy, right thoracotomy and a cervical incision - anastomosis in the neck. Safer if a leak occurs but higher voice and swallow issues.

  • Transhiatal

    Laparotomy plus a cervical incision - no thoracotomy. The oesophagus is bluntly dissected through the hiatus in selected patients.

  • Minimally invasive (MIO)

    Laparoscopic abdominal and thoracoscopic chest phases - smaller wounds, less pulmonary morbidity in the right hands.

  • Robot-assisted (RAMIE)

    Robotic platform for the thoracic phase - increasingly the UK standard at high-volume centres for suitable tumours.

  • Extended total gastrectomy + oesophagectomy

    For Siewert III subcardial tumours with distal oesophageal involvement - total gastrectomy plus a cuff of lower oesophagus, Roux-en-Y reconstruction.

  • Gastric conduit reconstruction

    Tubularised stomach brought up to meet the oesophageal remnant - the most common reconstruction when partial stomach remains.

  • Jejunal Roux-en-Y or colon interposition

    Jejunal Roux-en-Y for total gastrectomy scenarios; colon interposition is reserved as a salvage or complex-anatomy option.

Safety, outcomes and life after

What to expect - honestly.

Oesophagogastrectomy is major surgery with real risks and a permanent change to eating. 30-day mortality is 3–8% in high-volume UK centres; 5-year survival depends on stage. The complications below matter - plan for them.

  • Anastomotic leak - 5–15%

    The main serious early complication. Higher for chest anastomoses; lower for neck. Treated with drainage, stenting, nutrition and - rarely - re-operation.

  • Pulmonary complications

    Pneumonia and ARDS are the commonest problems after an oesophagogastrectomy. Prehab, incentive spirometry, epidural analgesia and early mobilisation matter more than most patients expect.

  • Cardiac arrhythmia - AF in 20–30%

    Atrial fibrillation is common in the first week. Usually settles with rate control; a small number need cardioversion or longer-term anticoagulation.

  • Recurrent laryngeal nerve palsy

    Injury near the neck anastomosis can leave a hoarse voice and increase aspiration risk. Most partial injuries recover; permanent palsy needs speech therapy input.

  • Delayed gastric emptying, chyle leak, DVT/PE

    The conduit can be slow to empty and may need pyloroplasty or Botox. Chylothorax, DVT and PE are recognised - prophylaxis is standard.

  • Anastomotic stricture

    Scar tightening at the join can cause dysphagia and may need repeated endoscopic dilatation - see our page on oesophageal dilatation.

  • Dumping, reflux, weight loss

    Small frequent meals, chewing well, avoiding drinking with food and staying upright after eating are the daily rules. Weight loss of 10–15% in the first year is common.

  • Lifelong B12, iron and calcium checks

    Loss of stomach and altered absorption mean B12 injections, iron and calcium/vitamin D need lifelong monitoring by the GP or specialist team.

  • Red flags after discharge

    Fever, chest pain, breathlessness, tachycardia, worsening abdominal pain, dark stools or new inability to swallow - same-day contact with the surgical team or A&E.

Reading your operation note

Your operation note in four parts. Read the last one first.

Whichever approach was used, the note the surgeon sends you keeps to the same shape.

A UK upper GI cancer surgeon reviewing a patient’s operation notes

A quiet reminder

Surgical language is precise and can read coldly - we translate it for you.

If you would like us to talk you through the note before your review, just ask.

  1. 01 Header

    Indication, Siewert type and neoadjuvant

    Why the operation was done - Siewert I, II or III - and which neoadjuvant regimen (FLOT or CROSS) preceded surgery.

  2. 02 Technique

    Approach and reconstruction

    Whether Ivor-Lewis, McKeown, transhiatal, MIO/RAMIE or extended total gastrectomy - and whether reconstruction used a gastric conduit or Roux-en-Y.

  3. 03 Findings

    Margins, nodes and pathology

    Resection margins (R0/R1), lymph node yield and involvement, tumour regression grade after neoadjuvant, and any incidental findings.

  4. 04 Impression

    Recovery plan, nutrition and surveillance

    Read this first: NG and jejunostomy timing, dietician plan, follow-up imaging schedule, and whether adjuvant chemotherapy is recommended.

Delivered on the NHS pathway · UK insurers for related private input

NHS pathwayBupaAXA HealthVitalityAvivaWPACignaNHS pathwayBupaAXA HealthVitalityAvivaWPACignaNHS pathwayBupaAXA HealthVitalityAvivaWPACigna

Oesophagogastrectomy itself is delivered on the NHS at a specialist upper GI centre. Private cover can support second opinions, imaging or nutritional review alongside the NHS pathway.

Frequently asked

Everything we get asked about oesophagogastrectomy.

Clear answers on Siewert type, chemotherapy, approach, recovery, risks and long-term survival.

  • What is an oesophagogastrectomy, and how is it different from an oesophagectomy?

    An oesophagectomy removes the oesophagus. An oesophagogastrectomy removes the distal (lower) oesophagus together with part or all of the stomach - done for tumours that straddle the gastro-oesophageal junction (GOJ) or extensive gastric cancers reaching up into the oesophagus. See our page on oesophagectomy for tumours confined to the oesophagus alone.

  • What is Siewert classification and why does it matter?

    Siewert classifies GOJ tumours by centre. Type I sits 1–5cm above the junction and is usually treated as an oesophagectomy with gastric conduit. Type II sits within 1cm above to 2cm below the junction - this is the classic oesophagogastrectomy. Type III sits 2–5cm below and is treated as extended total gastrectomy with a distal oesophagectomy. The type drives the operation, the approach and the reconstruction.

  • Do I need chemotherapy or chemoradiotherapy before surgery?

    For locally advanced tumours, yes. UK practice is peri-operative FLOT chemotherapy for GOJ and gastric adenocarcinoma, or CROSS chemoradiotherapy for tumours sitting more on the oesophageal side. The MDT decides based on histology, stage and fitness.

  • Which surgical approach will I have?

    It depends on Siewert type and your anatomy. Ivor-Lewis (abdomen plus right chest, chest anastomosis) is the workhorse. McKeown adds a neck incision and puts the join in the neck. Transhiatal avoids the chest entirely. MIO and RAMIE offer minimally invasive versions. Extended total gastrectomy with a lower oesophagectomy is used for Siewert III.

  • Is this available privately?

    Oesophagogastrectomy is a major cancer operation almost always delivered on the NHS pathway at a specialist upper GI cancer centre - that is where volume, MDT and ITU support live. Private second opinions on an MDT plan are available; the operation itself is not routinely done privately.

  • How long is recovery and when can I get back to normal?

    ITU is 24–72 hours, hospital 10–21 days, jejunostomy feeding 3–6 weeks, back to office work 8–12 weeks, and full return to normal activity 3–6 months. Eating patterns change permanently - small, frequent meals, chewing well, sitting upright afterwards.

  • What are the main risks?

    Early: anastomotic leak (5–15%), pneumonia and ARDS, atrial fibrillation (20–30%), MI, DVT/PE, chylothorax, recurrent laryngeal nerve palsy, delayed gastric emptying. Late: anastomotic stricture (may need dilatation), reflux, dumping syndrome, weight loss and B12/iron/calcium deficiency. 30-day mortality in high-volume UK centres is 3–8%.

  • What are the survival odds?

    Five-year survival depends on stage: over 70% for T1 disease, around 40% for T3, and 20–30% once nodes are involved. Neoadjuvant therapy, complete (R0) resection and a high-volume centre all move the numbers in your favour.

Related treatments

Looking for something else?